Saturday 17 October 2026 Export PODD’s income statement to Excel — free account

Insulet Corporation

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%

Follow PODD

Alert me

Market cap: $9.6B
P/E: 26.4×
Fwd P/E: 24.7×
Dividend yield: —
F-score: 6/9
Altman Z: 9.09
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Auditor change Dec 19, 2025

All filings →

Insider Decisions trades per month

Total buys 2.89

Total sells 0.60

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	2	—	—	—	2	—	1	—	—
Sell	—	1	—	—	—	—	—	1	—	—	—	—

Insider Ownership 0.36%

Capital & Financial Ratios $m

Market Cap 9,620.00

Revenue 3,053.40

Net Income 375.30

Free Cash Flow 265.60

Net Debt 413.50

Current Ratio 2.48

Debt/Equity 0.67

P/E ratio 26.37

Fwd P/E 24.70

P/S ratio 3.20

P/B ratio 6.88

Past 5Y EPS Growth 103.38%

This Y EPS Growth 30.93%

Next Y EPS Growth 18.68%

Next Y revenue growth 21.38%

Next 5Y EPS Growth 23.30%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 1.64%

10-year low 10-year high

P/S against its own 10 years 1.11%

10-year low 10-year high

P/B against its own 10 years 1.11%

10-year low 10-year high

EV/Sales against its own 10 years 1.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	704	953	716	535
Receivables	360	366	517	589
Inventory	403	430	453	485
Other	—	—	—	—
	1,583	1,891	1,914	1,849

	2023	2024	2025	Q'26
Payables	19	20	75	123
ST’ Debt	49	84	18	19
Other	—	—	—	—
	451	528	680	744

Compound Annual Growth %

	10y	5y	3y
Sales	26.22%	24.53%	27.54%
Cash Flow	0.00%	46.63%	68.50%
Earnings	0.00%	105.15%	277.32%
Book Value	46.16%	20.21%	47.06%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	762	802	—	—	—
’25	569	649	706	784	2,708
’24	442	489	544	598	2,072
’23	358	397	433	510	1,697
’22	295	299	341	370	1,305
’21	252	263	276	308	1,099
’20	198	226	234	246	904

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	114	88	—	—	—
’25	64	197	126	183	569
’24	88	87	108	148	430
’23	1	44	56	45	146
’22	(14)	25	57	51	119
’21	(35)	18	(26)	(25)	(68)
’20	(4)	26	44	17	84

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	86	51	—	—	—
’25	48	173	95	34	350
’24	64	62	79	92	296
’23	(37)	26	34	14	37
’22	(30)	6	23	(38)	(38)
’21	(68)	(5)	(55)	(62)	(191)
’20	(31)	2	18	(71)	(82)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.30	1.37	—	—	—
’25	0.50	0.32	1.24	1.44	3.48
’24	0.73	2.59	1.08	1.39	5.78
’23	0.34	0.39	0.74	1.44	2.94
’22	0.40	(0.50)	(0.08)	0.24	0.07
’21	0.00	(0.37)	0.18	0.42	0.24
’20	(0.03)	0.22	0.17	(0.26)	0.10

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	23.94	36.80	67.88	70.80	121.00	218.28	181.00	125.82	160.19	230.05	Analyst estimates 2026–2028 Powerpack
	High	45.60	72.99	108.91	187.25	269.42	324.81	320.00	335.91	279.77	354.88
People
People	Employees	640	857	1,169	1,350	1,900	2,300	2,600	3,000	3,900	5,400
	Revenue/emp, $m	0.57	0.54	0.48	0.55	0.48	0.48	0.50	0.57	0.53	0.50
Income, $m
Income, $m	Revenue	367	464	564	738	904	1,099	1,305	1,697	2,072	2,708
	Gross margin, %	57.52	59.77	65.66	65.06	64.39	68.45	61.72	68.35	69.79	71.63
	EBT	(27)	(27)	5	15	10	21	10	215	300	340
	EBT margin, %	(7.31)	(5.74)	0.92	1.96	1.07	1.87	0.75	12.65	14.49	12.54
	Net income	(29)	(27)	3	12	7	17	5	206	418	247
	Depreciation	14	14	16	28	55	57	63	73	81	90
Per share, $
Per share, $	Revenue	6.41	8.00	9.58	12.18	13.97	16.23	18.82	24.33	29.56	38.50
	Earnings	(0.50)	(0.46)	0.06	0.19	0.11	0.25	0.07	2.96	5.97	3.51
	Cash flow	0.28	0.71	0.61	1.62	1.30	(1.01)	1.72	2.09	6.14	8.09
	Capex	(0.39)	(1.33)	(2.76)	(2.82)	(2.57)	(1.81)	(2.27)	(1.57)	(1.91)	(3.12)
	Free cash flow	(0.11)	(0.62)	(2.15)	(1.20)	(1.27)	(2.82)	(0.55)	0.52	4.23	4.97
	Book value	1.10	2.73	3.60	1.25	9.32	8.22	6.87	10.50	17.29	21.54
	Shares, m	57	58	59	61	65	68	69	70	70	70
Valuation, ×
Valuation, ×	P/E	0.00	0.00	1,322.00	951.11	2,323.91	1,156.83	4,091.14	70.88	43.66	81.21
	P/S	5.83	8.63	8.28	14.05	18.30	16.39	15.22	8.59	8.83	7.38
	P/B	33.86	25.25	22.01	136.68	27.42	32.38	41.70	19.91	15.10	13.20
	EV/Sales	5.98	8.95	8.86	14.75	18.42	16.83	15.78	9.01	9.04	7.47
	EV/FCF	(354.03)	(127.76)	(38.46)	(150.20)	(201.94)	(96.93)	(537.72)	419.10	63.20	57.81
Cash, $m
Cash, $m	Operating cash flow	16	41	36	98	84	(68)	119	146	430	569
	Capex	(22)	(77)	(162)	(171)	(166)	(123)	(157)	(109)	(134)	(219)
	Free cash flow	(6)	(36)	(126)	(72)	(82)	(191)	(38)	37	296	350
Balance, $m
Balance, $m	Working capital	314	451	346	433	1,041	1,101	949	1,132	1,363	1,234
	Total debt	333	566	592	892	1,059	1,274	1,402	1,416	1,380	949
	Net debt	34	126	303	516	112	482	727	712	427	233
	Shareholders’ equity	63	159	212	76	604	556	476	733	1,212	1,515
Returns, %
Returns, %	ROA	(7.89)	(4.21)	0.38	1.12	0.45	0.86	0.21	8.53	14.74	7.87
	ROIC	(6.87)	(1.62)	3.32	5.28	4.50	7.58	1.95	9.52	11.79	16.94
	ROE	(59.42)	(24.18)	1.78	8.06	2.00	2.90	0.89	34.12	43.03	18.12

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
HAE Haemonetics Corporation	$5.5B	57.7×	18.0×	+5.60% (above 0%: growing)	+2.86% (above 0%: growing)	+220.38% (above 0%: growing)	59.76%	16.93%	Compare
Median of peers	$10.0B	43.1×	27.9×	+5.77%	−5.69%	+120.23%	63.85%	10.84%

All 149 Medical Devices stocks →

Insulet Corporation (PODD) key facts

Concern: Net income was $247.1 million, or $3.51 per share (basic), a net margin of 9.12%.
Strength: Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
Insulet Corporation (PODD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PODD traded at $141.10, a market capitalization of $9.6 billion.
At that price the stock trades at 26.4× trailing-twelve-month earnings and 3.2× sales; its P/E is higher than 2% of its own readings over the past ten years.
Return on equity was 18.1% and debt-to-equity 0.67.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 9.09 (safe zone) for fiscal 2025.